Bislenghi, Gabriele http://orcid.org/0000-0002-9212-9287
Fieuws, Steffen
Wolthuis, Albert
Vanbeckevoort, Dirk
Ferrante, Marc
Sabino, Joao
Vermeire, Severine
D’Hoore, André
Article History
Accepted: 8 January 2021
First Online: 22 January 2021
Compliance with ethical standards
: This research study was conducted retrospectively from data obtained for clinical purposes with all the procedures being performed were part of the routine care. Approval was obtained from the ethics committee of University of Leuven (S53684).
: All patients had consented for their data to be analyzed through the VLECC Biobank (Vlaamse Erfelijkheidsstudie Crohn’s en Colitis Ulcerosa, of Flemish Study for Genetics Research on Crohn’s Disease and Ulcerative Colitis).
: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. Further, all the possible conflicts of interest are now disclosed:Marc Ferrante:Research grant: Amgen, Biogen, Janssen, Pfizer, TakedaConsultancy: Abbvie, Boehringer-Ingelheim, Janssen, MSD, Pfizer, Sandoz, Takeda, ThermofisherSpeakers fee: Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, TakedaSeverine Vermeire:Receipt of grants/research supports: MSD, Abbvie, Takeda, Janssen, PfizerReceipt of honoraria or consultation fees: AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Shire, Pfizer Inc, Galapagos, Mundipharma, Hospira, Celgene, Second Genome, Progenity, Lilly, Arena, Gilead and JanssenParticipation in a company sponsored speaker’s bureau: AbbVie, MSD, Takeda, Ferring, Hospira, Pfizer, Janssen, and Tillots